142057-77-0

Basic information

• Product Name: DonepezilHcl
• Synonyms: 1-Benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine HCl;1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-((1-(phenylmethyl)-4-piperidinyl)methyl)-, hydrochloride;Aricept odt
• CAS NO: 142057-77-0
• Molecular Formula: C24H29NO3.HCl
• Molecular Weight: 0
• Mol File: 142057-77-0.mol
• Article Data: 55

Chemical Properties

• Appearance: /
• CAS DataBase Reference: DonepezilHcl(CAS DataBase Reference)
• NIST Chemistry Reference: DonepezilHcl(142057-77-0)
• EPA Substance Registry System: DonepezilHcl(142057-77-0)

Safety Data

• Hazardous Substances Data: 142057-77-0(Hazardous Substances Data)

Usage

Uses

Alzheimer’s disease treatment (adjunct); dementia symptoms treatment adjunct; cognition adjuvant; inhibitor (acetylcholinesterase).

Upstream product

• 120014-06-4 donepezil 
• 923571-17-9 1-benzyl-4-(5,6-dimethoxy-1-oxo-indane-2-carbonyl)-pyridinium bromide 
• 100-39-0 benzyl bromide 
• 120014-30-4 debenzyldonepezil 
• 100-44-7 benzyl chloride 
• 108-20-3 di-isopropyl ether 
• 259170-03-1 2-(3,4-dimethoxybenzyl)-3-(N-benzyl-4-piperidine)propionic acid 
• 923571-19-1 2-[(1-benzyl-1,2,3,6-tetrahydropyridin-4-yl)hydroxymethyl]-5,6-dimethoxyindan-1-one 
• 142057-79-2 (S)-donepezil 
• 142057-79-2 (R)-donepezil 
• 2107-69-9 5,6-dimethoxy-1-indanone 
• 2759-28-6 1-phenylmethylpiperazine 

Relevant articles and documents

Fractal analysis of catalyst surface morphologies on hydrogenation in process of 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydroinden-1- one hydrochloride synthesis

Catalytic hydrogenation of 2-((1-benzyl-1,2,3,6-tetrahydropyridin-4-yl) methylene)-5,6-dimethoxy-2,3-dihydroinden-1-one hydrochloride (1) to 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydroinden-1-one hydrochloride (2) was investigated in batch-slurry reactor. The 5% Pt/C catalysts were chosen for optimizing the catalytic activity. The catalyst activity has been changed by using the differently morphologically structured fractal catalysts. The kinetic terms of hydrogenation for (1) change with the fractal dimensions of the 5% Pt/C catalyst. The most active and selective (with the highest reaction rate for production of (2), and with the least impurities level) is the catalyst K3, and the worst the catalyst K4. This most active and selective catalyst has an intermediate fractal surface dimension, D F,ads = 2.77, and the worst catalyst is represented by almost smooth surface with a high DF,ads = 2.82. The interface D[BW] fractal indices (derived from the thresholded SEM images, at the magnifications in the range 600-2000×) are largest ones for the most suitable catalyst K3, and lowest for the catalyst K4.

Synthetic method of donepezil hydrochloride

The invention belongs to the technical field of medicines, and discloses a synthetic method of donepezil hydrochloride. The method comprises the following steps: taking 5, 6-dimethoxy-1-indanone and 4-pyridylaldehyde as initial raw materials, generating a

Purification method for Donepezil

The invention relates to a purification method for Donepezil and belongs to the technical field of preparation of raw pharmaceutical materials. The purification method for the Donepezil or pharmaceutically acceptable salts thereof, provided by the invention, comprises the steps: firstly, adding a hydrophobic organic solvent and water into the Donepezil or pharmaceutically acceptable salts thereof,so as to obtain a mixed solution, wherein the hydrophobic organic solvent is selected from dichloromethane, ethyl acetate, toluene and mixtures thereof; adjusting an aqueous phase pH of the mixed solution to be not smaller than 9 with alkali, and separating an organic phase from an aqueous phase; and subjecting the organic phase obtained in the step (3) to depressurized concentration, thereby obtaining purified Donepezil. According to the purification method for the Donepezil or pharmaceutically acceptable salts thereof, provided by the invention, high-quality raw pharmaceutical materials areprovided for preparations.